Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled trial of RO7105705 in Alzheimer's disease
2017-001800-31Phase 2Terminated
- Sponsor
- Genentech
- Start
- Oct 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing RO7105705 with Placebo (2 arms). Primary endpoint: Change from baseline on the CDR-Sum of Boxes. Started Oct 2017; status: terminated.
02
Drugs
semorinemab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2017-001800-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001800-31.